• Consensus Rating: Buy
  • Consensus Price Target: $4.25
  • Forecasted Upside: 214.81%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.35
▲ +0.05 (3.85%)

This chart shows the closing price for CNTG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Centogene Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNTG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNTG

Analyst Price Target is $4.25
▲ +214.81% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Centogene in the last 3 months. The average price target is $4.25, with a high forecast of $6.00 and a low forecast of $2.50. The average price target represents a 214.81% upside from the last price of $1.35.

This chart shows the closing price for CNTG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Centogene. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/14/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/12/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/11/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/23/2022HC WainwrightInitiated CoverageBuy$2.50Low
7/18/2022SVB LeerinkLower TargetOutperform$10.00 ➝ $6.00Low
12/22/2021UBS GroupDowngradeBuy ➝ NeutralMedium
11/28/2021Robert W. BairdReiterated RatingBuy$14.00Medium
9/8/2021Robert W. BairdBoost TargetOutperform$13.00 ➝ $15.00Low
6/27/2021SVB LeerinkReiterated RatingBuy$24.00Medium
6/20/2021BTIG ResearchReiterated RatingBuy$23.00Medium
6/17/2021Credit Suisse GroupLower TargetOutperform$15.00 ➝ $14.00Medium
4/18/2021Robert W. BairdReiterated RatingBuy$19.00High
12/16/2020SVB LeerinkReiterated RatingOutperformHigh
11/5/2020Credit Suisse GroupInitiated CoverageOutperform$15.00High
10/7/2020Kempen & CoInitiated CoverageBuy$22.00Medium
4/24/2020Robert W. BairdBoost TargetOutperform$15.00 ➝ $20.00Medium
4/24/2020BTIG ResearchBoost TargetBuy$18.00 ➝ $23.00Low
12/3/2019Robert W. BairdInitiated CoverageOutperform$15.00Medium
12/2/2019SVB LeerinkReiterated RatingOutperformHigh
12/2/2019Evercore ISIInitiated CoverageOutperform$17.00High
12/2/2019BTIG ResearchInitiated CoverageBuy$18.00High
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.12 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/11/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/10/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/9/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/9/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/8/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/7/2023

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Centogene logo
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing. The company develops rare disease platform, a data and biological repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs. It provides various services, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services to physicians, laboratories, or hospitals directly or through distributors. The company also offers COVID-19 testing solutions, including PCR and antigen testing services. It has collaboration and license agreements with Shire International GmbH, Pfizer Inc., Dr. Bauer Laboratoriums GmbH, Fraport AG, Takeda Pharmaceutical Company Limited, and Twist Bioscience Corporation. Centogene N.V. was founded in 2006 and is headquartered in Rostock, Germany.
Read More

Today's Range

Now: $1.35
Low: $1.35
High: $1.45

50 Day Range

MA: $0.96
Low: $0.72
High: $1.35

52 Week Range

Now: $1.35
Low: $0.68
High: $4.94

Volume

41,233 shs

Average Volume

26,156 shs

Market Capitalization

$36.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Centogene?

The following equities research analysts have issued reports on Centogene in the last year: HC Wainwright, and SVB Leerink LLC.
View the latest analyst ratings for CNTG.

What is the current price target for Centogene?

2 Wall Street analysts have set twelve-month price targets for Centogene in the last year. Their average twelve-month price target is $4.25, suggesting a possible upside of 214.8%. SVB Leerink LLC has the highest price target set, predicting CNTG will reach $6.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.50 for Centogene in the next year.
View the latest price targets for CNTG.

What is the current consensus analyst rating for Centogene?

Centogene currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNTG will outperform the market and that investors should add to their positions of Centogene.
View the latest ratings for CNTG.

What other companies compete with Centogene?

How do I contact Centogene's investor relations team?

Centogene's physical mailing address is AM STRANDE 7, ROSTOCK 2M, 18055. The company's listed phone number is 38180113500 and its investor relations email address is [email protected] The official website for Centogene is www.centogene.com. Learn More about contacing Centogene investor relations.